Cargando…

Kinase-independent role for CRAF-driving tumour radioresistance via CHK2

Although oncology therapy regimens commonly include radiation and genotoxic drugs, tumour cells typically develop resistance to these interventions. Here we report that treatment of tumours with ionizing radiation or genotoxic drugs drives p21-activated kinase 1 (PAK1)-mediated phosphorylation of CR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Advani, Sunil J., Camargo, Maria Fernanda, Seguin, Laetitia, Mielgo, Ainhoa, Anand, Sudarshan, Hicks, Angel M., Aguilera, Joseph, Franovic, Aleksandra, Weis, Sara M., Cheresh, David A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Pub. Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559870/ https://www.ncbi.nlm.nih.gov/pubmed/26333361 http://dx.doi.org/10.1038/ncomms9154

Ejemplares similares

A MEK-independent role for CRAF in mitosis and tumor progression
por: Mielgo, Ainhoa, et al.
Publicado: (2011)

MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment
por: Wilson, RaeAnna, et al.
Publicado: (2016)

Selective CRAF Inhibition Elicits Transactivation
por: Morgan, Charles W., et al.
Publicado: (2021)

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
por: Heidorn, Sonja J., et al.
Publicado: (2010)

Oncogenic RAS drives the CRAF‐dependent extracellular vesicle uptake mechanism coupled with metastasis
por: Choi, Dongsic, et al.
Publicado: (2021)

Targeting the Achilles’ heel of drug-resistant cancer stem cells
por: Seguin, Laetitia, et al.
Publicado: (2014)

Registered report: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
por: Bhargava, Ajay, et al.
Publicado: (2016)

Increased activity of CHK enhances the radioresistance of MCF-7 breast cancer stem cells
por: YANG, ZHI-XUE, et al.
Publicado: (2015)

CRAF R391W is a melanoma driver oncogene
por: Atefi, Mohammad, et al.
Publicado: (2016)

ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1
por: Zhang, Peijing, et al.
Publicado: (2014)

SALL4 induces radioresistance in nasopharyngeal carcinoma via the ATM/Chk2/p53 pathway
por: Nie, Xin, et al.
Publicado: (2019)

Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors
por: Chatelle, Claire V., et al.
Publicado: (2016)

Three distinct regions of cRaf kinase domain interact with membrane
por: Prakash, Priyanka, et al.
Publicado: (2019)

Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress
por: Zhang, Yao, et al.
Publicado: (2016)

Impaired neuronal maturation of hippocampal neural progenitor cells in mice lacking CRAF
por: Pfeiffer, Verena, et al.
Publicado: (2018)

UBE2T-regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation
por: Sun, Jingyuan, et al.
Publicado: (2020)

Chk1, Chk2, is the amplifier on?
por: Dove, Alan W.
Publicado: (2001)

Targeting the prohibitin scaffold-CRAF kinase interaction in RAS-ERK-driven pancreatic ductal adenocarcinoma
por: Luan, Zhou, et al.
Publicado: (2014)

Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and MEK1/2
por: Wang, Penglei, et al.
Publicado: (2023)

Sirt3 Promoted DNA Damage Repair and Radioresistance Through ATM-Chk2 in Non-small Cell Lung Cancer Cells
por: Cao, Kun, et al.
Publicado: (2021)

Impact of tumour associated macrophages in pancreatic cancer
por: Mielgo, Ainhoa, et al.
Publicado: (2013)

Tumour growth environment modulates Chk1 signalling pathways and Chk1 inhibitor sensitivity
por: Massey, Andrew J.
Publicado: (2016)

Cancer-Associated Fibroblast Mediated Inhibition of CD8+ Cytotoxic T Cell Accumulation in Tumours: Mechanisms and Therapeutic Opportunities
por: Freeman, Patrick, et al.
Publicado: (2020)

Long noncoding RNA LINC02582 acts downstream of miR-200c to promote radioresistance through CHK1 in breast cancer cells
por: Wang, Baiyao, et al.
Publicado: (2019)

X-linked Inhibitor of Apoptosis Protein negatively regulates neuronal differentiation through interaction with cRAF and Trk
por: Fadó, Rut, et al.
Publicado: (2013)

A CRAF/glutathione-S-transferase P1 complex sustains autocrine growth of cancers with KRAS and BRAF mutations
por: Niitsu, Yoshiro, et al.
Publicado: (2020)

CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition
por: Noeparast, Amir, et al.
Publicado: (2019)

Implications of glutathione-S transferase P1 in MAPK signaling as a CRAF chaperone: In memory of Dr. Irving Listowsky
por: NIITSU, Yoshiro, et al.
Publicado: (2022)

Regulation of Chk1
por: Tapia-Alveal, Claudia, et al.
Publicado: (2009)

Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors
por: Jaiswal, Bijay S., et al.
Publicado: (2009)

A Novel Class of Small Molecule Compounds that Inhibit Hepatitis C Virus Infection by Targeting the Prohibitin-CRaf Pathway
por: Liu, Shufeng, et al.
Publicado: (2015)

CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles
por: Jain, P, et al.
Publicado: (2017)

The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking phospho–Ser-621 in the C terminus of CRAF
por: Yuan, Jimin, et al.
Publicado: (2018)

Keeping RelApse in Chk: molecular mechanisms of Chk1 inhibitor resistance in lymphoma
por: Black, Elizabeth M., et al.
Publicado: (2022)

Polo-like kinase 1 induces epithelial-to-mesenchymal transition and promotes epithelial cell motility by activating CRAF/ERK signaling
por: Wu, Jianguo, et al.
Publicado: (2016)

Stroke Risk Status, Anticoagulation Treatment, and Quality-of-Life in Chinese Patients with Atrial Fibrillation: China Registry of Atrial Fibrillation (CRAF)
por: Sun, Yihong, et al.
Publicado: (2019)

Targeting the Surface of the Protein 14‐3‐3 by Ultrasmall (1.5 nm) Gold Nanoparticles Carrying the Specific Peptide CRaf
por: Ruks, Tatjana, et al.
Publicado: (2021)

Sex disparities in non-small cell lung cancer: mechanistic insights from a cRaf transgenic disease model
por: Zhong, Shen, et al.
Publicado: (2023)

Regulation, targets and functions of CHK
por: Zhu, Shudong, et al.
Publicado: (2022)

Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy
por: Manic, Gwenola, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vr6rf7jmbn753fm4c4j3qrtf8p